ClinicalTrials.gg
RecruitingNCT07279493KPCXM18Updated Dec 12, 2025

Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke

A Phase 2 interventional study of The KPCXM18 injection and Placebo in Acute Ischemic Stroke, sponsored by Kunming Pharmaceuticals, Inc.. Recruiting at 23 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Kunming Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 750 studies in Ischemic Stroke with a site in China — 377 open to participants now, 396 under way, 76 of them phase 3. Ischemic Stroke · China.

Planned enrollment
258th of 563
300 · median 266
Started
2025
with 106 others
Phase 2
71 of 750
29 open now
Primary completion
2026-10
later than 132 of 395 live
Registered
619th of 750
by date

Among the 750 studies in Ischemic Stroke with a site in China, this one is the 258th largest by planned enrollment of the 563 interventional ones that give a count, is one of 107 that started in 2025, is one of 71 in phase 2, reaches primary completion later than 132 of the 395 other live ones, and was the 619th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

377 of the 750 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

372 more — sign in →

All 377 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 750 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, double-blind, parallel, placebo-controlled trial design to evaluate the efficacy and safety of the KPCXM18 injection at different doses for the treatment of acute ischemic stroke.

Read the detailed description

Trial Objectives:

The primary objective is to evaluate the efficacy of the KPCXM18 injection at different doses for the treatment of acute ischemic stroke.

The secondary objective is to evaluate the safety of the KPCXM18 injection at different doses for the treatment of acute ischemic stroke and based on the population pharmacokinetic analysis method, explore the PK characteristics of the KPCXM18 injection in patients with acute ischemic stroke, and provide a basis for the design of the phase III clinical study.

Trial Design:

This trial is a multicenter, randomized, double-blind, parallel, placebo-controlled design. The subjects will be randomly assigned to the low-dose group, the high-dose group, and the placebo group at a ratio of 1:1:1, with 100 subjects in each group, totaling 300 subjects. The treatment will be administered continuously for 12±2 days to explore the efficacy and safety of the KPCXM18 injection at different doses for the treatment of acute ischemic stroke.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Age 18 to 80 years old (including 18 years old and 80 years old, based on the date of signing the form), male or female;
  • 2.Diagnosed with acute ischemic stroke according to the " Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2023 ";
  • 3.During the screening process, it is required that the ischemic stroke should occur within 12 hours after the onset, and it is expected that the drug can be started within 12 hours after the onset; note: The onset time is calculated from the time when the ischemic stroke symptoms appear, If the onset occurs during sleep, the time of onset should be considered as the last time the patient was observed to be normal;
  • 4.Before intravenous thrombolysis, 6 points ≤ NIHSS score ≤ 24 points, and the sum of upper limb and lower limb score ≥2 points;
  • 5.The patients who first attacked, or the patients who had a good prognosis after the last attacked , (mRS score was ≤1 before the onset of the disease );
  • 6.The subject has received or plans to receive standard intravenous thrombolysis treatment after this onset;
  • 7.The subject can understand and follow the research process and voluntarily signs the research informed consent form (the informed consent form is signed by the subject or the legal representative).

Exclusion criteria

Exclusion Criteria:

  • 1. Patients with intracranial hemorrhagic diseases confirmed by Imaging: hemorrhagic stroke, epidural hematoma, intracranial hematoma, subarachnoid hemorrhage, ventricular hemorrhage, Traumatic cerebral hemorrhage, etc;
  • 2. Patients who have received or plan to receive endovascular interventional treatment (including endovascular mechanical thrombectomy, intravascular thrombus aspiration, arterial thrombolysis, angioplasty and stenting) or patients with arteriovenous bridging therapy after this onset;
  • 3. Patients with disturbance of consciousness (NIHSS score Ia>1 point);
  • 4. Patient has a history of intracranial hemorrhage before;
  • 5. Patient who have a history of epilepsy or who experienced epileptic symptoms during a stroke;
  • 6. The patient with other mental illness (such as severe mental disorders, dementia) and combined conditions such as limb movement disorders may influence their neurological function tests;
  • 7. Patients with acute myocardial infarction, cardiac interventional therapy, or heart failure (grade III and IV according to ) within the past 1 month;
  • 8. Patients with malignant tumors, serious diseases of blood, digestion or other systems or diseases with bleeding tendencies (such as hemophilia, etc.), and the expected survival time is not more than 3 months;
  • 9. Despite active antihypertensive therapy, hypertension remains uncontrolled: systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥100 mmHg;
  • 10.Patients with severe liver function impairment, or , AST > 2.0× ;
  • 11.Patients with severe renal impairment, or serum creatinine > 1.5× ULN;
  • 12.Patients who have used neuroprotective drugs (including Edaravone, Edaravone Dexborneol, Butylphthalide, Piracetam, Urinary Kallidinogenase, Ginkgolide, Ginkgo Diterpene Lactone, Safflower Extract and Aceglutamide Injection, etc.) after the onset of this illness;
  • 13.Patients with severe allergies, to at least two or more types of drugs, or known to be allergic to any ingredient or of the drug;
  • 14.Patients with a history of major surgery within 1 month before screening;
  • 15.Patients with a history of drug abuse within 3 month before screening;
  • 16.Patients who participated in or are currently participating in other clinical trials within 3 month prior to this study;
  • 17.Pregnancy, lactation. or patients who have a family plan within 3 months of the first dose and who are unwilling to use ;
  • 18.The investigator considers that patients are not suitable for clinical trials.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    low-dose group (The KPCXM18 injection)

    The KPCXM18 injection (60 mg BID)

    Drug: The KPCXM18 injection

  • Experimental
    high-dose group (The KPCXM18 injection)

    The KPCXM18 injection (100 mg BID)

    Drug: The KPCXM18 injection

  • Placebo comparator
    Placebo

    Placebo of the KPCXM18 injection( BID )

    Drug: Placebo

Interventions

  • DrugThe KPCXM18 injection

    Intravenous infusion of 60 mg twice daily at intervals of 12±2 hours for 12±2 days.

  • DrugPlacebo

    Intravenous infusion twice a day with an interval of 12±2 hours for 12±2 days.

  • DrugThe KPCXM18 injection

    Intravenous infusion of 100 mg twice daily at intervals of 12±2 hours for 12±2 days.

06

What researchers measure

Primary outcomes

  1. Modified Rankin Scale (mRS), with scores of 0-1 at Day 90

    Proportion of subjects with mRS score ≤ 1 at day 90 after administration

    Time frame: day 90

Secondary outcomes

  1. Modified Rankin Scale (mRS), with scores of 0-1 at day 12±2 and 30

    Proportion of subjects with mRS score ≤ 1 at day 12±2 and 30 after administration

    Time frame: days 12±2 and 30

  2. Modified Rankin Scale (mRS), with scores of 0-2 at days 12±2, 30 and 90

    Proportion of subjects with mRS score ≤ 2 at day 12±2, 30, 90 after administration

    Time frame: days 12±2, 30 and 90

  3. MRS Shift analysis

    MRS shift analysis at day 90 after administration

    Time frame: day 90

  4. National Institute of Health stroke scale (NIHSS) on day 12±2

    Proportion of subjects with NIHSS score ≤ 1 or with ≥4 point reduction from baseline at day 12±2 after administration

    Time frame: days 12±2

  5. National Institute of Health stroke scale (NIHSS) on day 12±2

    Change in NIHSS score from baseline at day 12±2 after administration

    Time frame: days 12±2

  6. Barthel index (BI) at Day 90

    Proportion of subjects with BI score ≥95 at day 90 after administration

    Time frame: days 90

  7. Barthel index (BI) at Day 90

    Proportion of subjects with BI score ≥75 at day 90 after administration

    Time frame: days 90

07

Study locations

23 of 23 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Oct 2026, 10 months after the start.

Of 41 industry-sponsored phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 35. This study's planned 10 months is below that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2025
First posted
Dec 12, 2025
StartActual
Nov 22, 2025
Primary completionEst.
Oct 18, 2026
CompletionEst.
Oct 18, 2026
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07279493
Lead sponsor
Kunming Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Dec 12, 2025
Start date
Nov 22, 2025
Primary completion
Oct 18, 2026 (estimated)
Completion
Oct 18, 2026 (estimated)
Last update
Dec 12, 2025

Study contacts

Duo Gao, bachelor
Contact
GAODUO5@kpc.com.cn
0871-68319868-3052
Yongjun Wang, MD
principal investigator · Beijing Tiantan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion